Last reviewed · How we verify

NCT06079554

Microbiota and Metabolomics of Intestinal Type of Gastric Cancer

Recruiting now Last updated 12 April 2024
What this trial tests

trial in Gastric Cancer in 32 participants. Currently enrolling.

Timeline
31 March 2024
Primary endpoint
28 April 2024
30 August 2025

Quick facts

Lead sponsorJilin University
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment32
Start date31 March 2024
Primary completion28 April 2024
Estimated completion30 August 2025
Sites1 location across China

Conditions studied

Sponsor

Jilin University

Who can join

Adults 18 to 80, any sex, with Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Compare with the gastric cavity without cancerous transformation in atrophic gastritis, analyze the microbiota and metabolomics changes in intestinal type of gastric cancer under the background of atrophic gastritis, and explore the relevant mechanisms.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Gastric Cancer

Currently open trials in the same condition.

Other Jilin University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06079554.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing